Jeffrey Tyner

Associate Professor

Associate Professor, Knight Cancer Institute

Emailtynerj@ohsu.edu

Source: Scopus
Calculated based on no. of publications stored in Pure and citations from Scopus

Research activity per year

If you made any changes in Pure these will be visible here soon.

Fingerprint

Dive into the research topics where Jeffrey Tyner is active. These topic labels come from the works of this person. Together they form a unique fingerprint.

12 Similar Profiles

Network

Recent external collaboration on country level. Dive into details by clicking on the dots.

2 Finished
3 Not started

Functional Genomic Discovery of Pathway Targeted and Immune Modulatory Therapeutic Combinations in Hematologic Malignancies
Druker, B. & Tyner, J.
Project: Research project
Tumor Intrinsic and Microenvironmental Mechanisms Driving Drug Combination Efficacy and Resistance in AML
Druker, B., Tyner, J. & Agarwal, A.
Project: Research project
Targeting PTPN11 dependent Hematologic Malignancies
Chang, B. & Tyner, J.
Project: Research project
Pathogenetic Mechanism and Clinical Targeting of CSF3R-Driven Cancer
Tyner, J.
National Institutes of Health
4/1/14 → 2/28/19
Project: Research project
ROR1 as a Therapeutic Target in Acute Lymphoblastic Leukemia
Tyner, J.
National Institutes of Health
9/1/10 → 8/31/16
Project: Research project

7404 Citations
44 h-Index
136 Article
15 Review article
11 Letter
5 Comment/debate
More
- 2 Chapter
- 2 Short survey

An expanded universe of cancer targets
the Cancer Target Discovery and Development Network, Mar 4 2021, In: Cell. 184, 5, p. 1142-1155 14 p.
Research output: Contribution to journal › Review article › peer-review
3 Scopus citations
Antileukemic efficacy of a potent artemisinin combined with sorafenib and venetoclax
Moses, B. S., McCullough, S., Fox, J. M., Mott, B. T., Bentzen, S. M., Kim, M. J., Tyner, J. W., Lapidus, R. G., Emadi, A., Rudek, M. A., Kingsbury, T. J. & Civin, C. I., Feb 9 2021, In: Blood Advances. 5, 3, p. 711-724 14 p.
Research output: Contribution to journal › Article › peer-review

Open Access
Concomitant use of a dual Src/ABL kinase inhibitor eliminates the in vitro efficacy of blinatumomab against Ph⁺ ALL
Leonard, J. T., Kosaka, Y., Malla, P., LaTocha, D., Lamble, A., Hayes-Lattin, B., Byrd, K., Druker, B. J., Tyner, J. W., Chang, B. H. & Lind, E., Feb 18 2021, In: Blood. 137, 7, p. 939-944 6 p.
Research output: Contribution to journal › Article › peer-review

Open Access
1 Scopus citations
DNA methylation epitypes highlight underlying developmental and disease pathways in acute myeloid leukemia
Giacopelli, B., Wang, M., Cleary, A., Wu, Y. Z., Schultz, A. R., Schmutz, M., Blachly, J. S., Eisfeld, A. K., Mundy-Bosse, B., Vosberg, S., Greif, P. A., Claus, R., Bullinger, L., Garzon, R., Coombes, K. R., Bloomfield, C. D., Druker, B. J., Tyner, J. W., Byrd, J. C. & Oakes, C. C., 2021, In: Genome Research. 31, 5, p. 747-761 15 p.
Research output: Contribution to journal › Article › peer-review

Open Access
Proteogenomic and metabolomic characterization of human glioblastoma
Clinical Proteomic Tumor Analysis Consortium, Apr 12 2021, In: Cancer Cell. 39, 4, p. 509-528.e20
Research output: Contribution to journal › Article › peer-review

Open Access
2 Scopus citations